MDWD Share Price Performance
US$16.46
-2.19 (-11.74%)
46.3% undervalued intrinsic discount
US$30.67
Fair Value
Price US$16.46
AnalystConsensusTarget US$30.67
AnalystHighTarget US$39.00
AnalystLowTarget US$25.00
Fair ValueUS$30.67
Share Pricen/a
MediWound Ltd. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
MDWD Community Narratives
AN
Fair Value
·Fair Value US$30.67 46.3% undervalued intrinsic discount
Advanced Wound Care Demand Will Unlock Global Opportunities
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value
·Fair Value US$39 57.8% undervalued intrinsic discount
EscharEx Trials And Aging Populations Will Expand Wound Markets
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$25 34.2% undervalued intrinsic discount
Regulatory Delays Will Restrict Growth Though Future Promise Emerges
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Regulatory Delays Will Restrict Growth Though Future Promise Emerges
Key Takeaways Heavy reliance on a single product and late-stage trial uncertainty pose significant risks to revenue growth and earnings stability. Rising costs, regulatory delays, and increased competition threaten long-term margin expansion and market share gains.Read more
AN
US$25
34.2% undervalued intrinsic discount
Fair Value
Profit Margin
23.22%
Future PE
41.36x
Price in 2028
US$31.67
EscharEx Trials And Aging Populations Will Expand Wound Markets
Key Takeaways Strategic partnerships and regulatory tailwinds position MediWound to potentially dominate its market, with rapid adoption expected post-approval and significant upside to revenue outlooks. Government contracts and strong global demand are poised to drive long-term growth, boost margins, and open robust new channels for non-dilutive revenues.Read more
AN
US$39
57.8% undervalued intrinsic discount
Fair Value
Profit Margin
23.22%
Future PE
59.49x
Price in 2028
US$49.4
Advanced Wound Care Demand Will Unlock Global Opportunities
Key Takeaways Expanding manufacturing and favorable reimbursement shifts are expected to unlock suppressed product demand, boost sales, and improve gross margins. Diversification through ongoing clinical trials, new product launches, and public sector partnerships should reduce risk and strengthen long-term financial stability.Read more
AN
US$30.67
46.3% undervalued intrinsic discount
Fair Value
Profit Margin
23.22%
Future PE
37.84x
Price in 2028
US$38.84
Trending Discussion
Recently Updated Narratives
AN
Regulatory Delays Will Restrict Growth Though Future Promise Emerges
Fair Value: US$25 34.2% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
EscharEx Trials And Aging Populations Will Expand Wound Markets
Fair Value: US$39 57.8% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Advanced Wound Care Demand Will Unlock Global Opportunities
Fair Value: US$30.67 46.3% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
MediWound Ltd. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
May 27, 2026
- -1.86
- 19.19%
- -140.80%
- 0%
About MDWD
- Founded
- 2000
- Employees
- 121
- CEO
- WebsiteView website
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
